Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Ropinirole, Parkinson's disease, dopamine agonist
Eligibility Criteria
Inclusion Criteria: Patients must give written informed consent prior to any specific study procedures. Males or females; females of childbearing age who are not currently pregnant must agree to use a medically accepted method of contraception throughout the study. Age greater than or equal to 25 years. Patients must be on a maximum dose of dopamine agonist drug (pergolide 4mg/day, pramipexole 4.5 mg/day or ropinirole 24mg/day). Stable dose of all medications for 4 weeks. Exclusion Criteria: Current hallucinations. History of disabling hallucinations or hallucinations in past requiring treatment. Troublesome edema (swelling). Unstable depression. Female who is pregnant or lactating. Use of an investigational drug with in the last 30 days. Other inclusion or exclusion criteria to be evaluated by the physician.
Sites / Locations
- Colorado Neurology, P.C.Recruiting